Phenethyl Isothiocyanate

苯乙基异硫氰酸酯

Report date: 2022/09/23 14:16:32
NME

Base Information

Drug NamePhenethyl Isothiocyanate
Drug Alias Name豆瓣菜素苯基乙基异硫代氰酸酯异硫氰酸苯乙酯JC-5411
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTranscription factor Sp1 inhibitorsApoptosis inducersc-Jun N-terminal kinase activators +[4] 
TargetsTranscription factor Sp1c-Jun N-terminal kinaseMitogen-activated protein kinase; ERK1/ERK2
Therapy Area/IndicationsSolid tumoursTobacco Use DisorderLymphoproliferative Disorders +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesUniversity Of MinnesotaJC (Wuxi) Company Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJC (Wuxi) Company Inc
Inactive CompaniesGeorgetown UniversityUniversity Of MinnesotaNational Cancer Institute +[4] 
Active IndicationsSolid tumoursProstatic HyperplasiaProstatic Neoplasms
Inactive IndicationsTobacco Use DisorderLymphoproliferative DisordersLung Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksWikipedia